These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 3936558)

  • 1. Pharmacokinetic evaluation of novel sustained-release dosage forms of valproic acid in humans.
    Bialer M; Friedman M; Dubrovsky J; Raz I; Abramsky O
    Biopharm Drug Dispos; 1985; 6(4):401-11. PubMed ID: 3936558
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative pharmacokinetic analysis of a novel sustained release dosage form of valproic acid in dogs.
    Bialer M; Friedman M; Dubrovsky J
    Biopharm Drug Dispos; 1984; 5(1):1-10. PubMed ID: 6423010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of valproic acid obtained after administration of three oral formulations to humans.
    Bialer M; Hussein Z; Dubrovsky J; Raz I; Abramsky O
    Isr J Med Sci; 1984 Jan; 20(1):46-9. PubMed ID: 6421770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of valproic acid after administration of three oral formulations in healthy adults.
    Bano G; Gupta S; Gupta KL; Raina RK
    J Assoc Physicians India; 1990 Sep; 38(9):629-30. PubMed ID: 2266076
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bioequivalence studies of a new valproic acid delayed-release capsule and divalproex sodium delayed-release tablet.
    Garikipati V; Toops DS; Fang Q
    Curr Med Res Opin; 2008 Jul; 24(7):1869-76. PubMed ID: 18593524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct absorption characteristics of oral formulations of valproic acid/divalproex available in the United States.
    Dutta S; Reed RC
    Epilepsy Res; 2007 Mar; 73(3):275-83. PubMed ID: 17208410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of sustained-release on the pharmacokinetics of theophylline in healthy subjects.
    Bialer M; Salame K; Raz I
    Int J Clin Pharmacol Ther Toxicol; 1985 Dec; 23(12):662-7. PubMed ID: 4093206
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A single-dose, three-period, six-sequence crossover study comparing the bioavailability of solution, suspension, and enteric-coated tablets of magnesium valproate in healthy Mexican volunteers under fasting conditions.
    Marcelín-Jiménez G; Angeles-Moreno AP; Contreras-Zavala L; Morales-Martínez M; Rivera-Espinosa L
    Clin Ther; 2009 Sep; 31(9):2002-11. PubMed ID: 19843490
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential pharmacokinetics of diclofenac potassium for oral solution vs immediate-release tablets from a randomized trial: effect of fed and fasting conditions.
    Chen C; Bujanover S; Kareht S; Rapoport AM
    Headache; 2015 Feb; 55(2):265-75. PubMed ID: 25546369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic characteristics of a new multiple unit sustained release formulation of sodium valproate.
    Wangemann M; Retzow A; Vens-Cappell B
    Int J Clin Pharmacol Ther; 1999 Feb; 37(2):100-8. PubMed ID: 10082174
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers.
    Bialer M; Rubinstein A; Raz I; Abramsky O
    Eur J Clin Pharmacol; 1984; 27(4):501-3. PubMed ID: 6440792
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative absorption profiles of divalproex sodium delayed-release versus extended-release tablets -- clinical implications.
    Dutta S; Reed RC; O'Dea RF
    Ann Pharmacother; 2006 Apr; 40(4):619-25. PubMed ID: 16569797
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Absolute bioavailability and absorption characteristics of divalproex sodium extended-release tablets in healthy volunteers.
    Dutta S; Reed RC; Cavanaugh JH
    J Clin Pharmacol; 2004 Jul; 44(7):737-42. PubMed ID: 15199078
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of oral sustained release clonidine in humans.
    MacGregor TR; Relihan GL; Keirns JJ
    Arzneimittelforschung; 1985; 35(1A):440-6. PubMed ID: 4039184
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bioavailability of a slow-release preparation of valproic acid under steady-state conditions.
    Klotz U
    Int J Clin Pharmacol Ther Toxicol; 1982 Jan; 20(1):24-6. PubMed ID: 6799412
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bioavailability of rectally administered valproic acid syrup.
    Cloyd JC; Kriel RL
    Neurology; 1981 Oct; 31(10):1348-52. PubMed ID: 6810203
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bioavailability and pharmacokinetics of theophylline in plain uncoated and sustained-release dosage forms in relation to smoking habit. I. Single dose study.
    Horai Y; Ishizaki T; Sasaki T; Chiba K; Suganuma T; Echizen H; Ohnishi A
    Eur J Clin Pharmacol; 1983; 24(1):79-87. PubMed ID: 6832206
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Relation between absorption half-life values of four novel sustained-release dosage forms of valproic acid in dogs and humans.
    Bialer M; Friedman M; Dubrovsky J
    Biopharm Drug Dispos; 1986; 7(5):495-500. PubMed ID: 3096397
    [No Abstract]   [Full Text] [Related]  

  • 19. Pharmacokinetic comparison of two valproic acid formulations--a plain and a controlled release enteric-coated tablets.
    Rha JH; Jang IJ; Lee KH; Chong WS; Shin SG; Lee N; Myung HJ
    J Korean Med Sci; 1993 Aug; 8(4):251-6. PubMed ID: 8198761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioequivalence of a new sustained-release formulation of sodium valproate, valproate modified-release granules, compared with existing sustained-release formulations after once- or twice-daily administration.
    Dulac O; Alvarez JC
    Pharmacotherapy; 2005 Jan; 25(1):35-41. PubMed ID: 15767218
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.